院内心脏骤停终止复苏规则的外部验证
该观察性研究利用美国心脏协会Get With The Guidelines-Resuscitation登记库2012-2024年前瞻性收集的院内心脏骤停队列,纳入646794例中的359686例成人患者(≥18岁),覆盖703家医院,外部验证既往推导的终止复苏规则。主要终点为存活出院,总体存活出院率为23.1%。对于主要验证的斯堪的纳维亚规则1(无目击、无监护、心搏停止、10分钟内未恢复自主循环),阳性率为1.7%,其中32.9%恢复自主循环,5.1%存活出院;每例符合规则1者中位可避免复苏时间11分钟,相当于每100次事件约18分钟。各医院阳性率范围为0%至11.9。其他终止规则要么平均阳性率极低(<3%),要么符合规则者存活率不可接受。排除COVID-19时代的敏感性分析结果相似。结论指出这些规则在美国临床采用前需进一步改进。
要点
- 斯堪的纳维亚规则1(无目击、无监护、心搏停止、10分钟内未恢复自主循环)阳性率仅1.7%,其中5.1%存活出院,提示可导致约5%存活者被过早终止复苏。
- 其他终止规则平均阳性率极低(<3%)或符合规则者存活率不可接受,均不适用于本美国院内心脏骤停队列。
- 每例符合规则1者中位可避免复苏时间11分钟,相当于每100次事件约18分钟。
- 各医院间规则1阳性率差异大(0%至11.9),提示规则在不同医院间适用性不一致。
- 排除COVID-19时代的敏感性分析结果与主分析相似。
适用人群与场景
- 成人患者(≥18岁)发生院内心脏骤停,来自美国心脏协会Get With The Guidelines-Resuscitation登记库参与医院,2012-2024年前瞻性收集队列。
诊断标准与关键阈值
- 斯堪的纳维亚终止规则1:无目击、无监护、心搏停止、10分钟内未恢复自主循环。
研究设计与关键结果
- 研究类型:观察性研究,前瞻性收集的院内心脏骤停队列,2012-2024年,来自美国心脏协会Get With The Guidelines-Resuscitation登记库参与医院;646794例中359686例符合纳入标准,覆盖703家医院。
- 总体存活出院率为23.1%。
- 斯堪的纳维亚规则1阳性率1.7%,其中32.9%恢复自主循环,5.1%存活出院;每例符合规则1者中位可避免复苏时间11分钟,相当于每100次事件约18分钟。
- 各医院规则1阳性率范围为0%至11.9。
- 其他终止规则平均阳性率极低(<3%)或符合规则者存活率不可接受。
- 排除COVID-19时代的敏感性分析结果相似。
证据类型、等级与局限
- 证据类型:观察性研究(前瞻性收集的院内心脏骤停队列的外部验证)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些终止规则在美国临床采用前需进一步改进。
- 斯堪的纳维亚规则1在美国队列中仅识别极少数患者(阳性率1.7%),且会导致约5%存活者被过早终止复苏。
- 其他终止规则因平均阳性率极低(<3%)或符合规则者存活率不可接受,不适用于该美国院内心脏骤停人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Termination of resuscitation rules aim to avoid prolonged, futile resuscitative efforts, reducing patient and provider burden. To date, however, no widely adopted rule exists for termination of in-hospital cardiac arrest. A recent study derived a termination rule (unwitnessed, unmonitored, asystole, and no return of spontaneous circulation within 10 min) in a Scandinavian cohort with an acceptably high positive rate for clinical utility and a very low rate of patients meeting the rule who survived to 30-days.
OBJECTIVE: To externally validate previously derived termination of resuscitation rules for patients suffering in-hospital cardiac arrest.
DESIGN: Observational study of a prospectively collected in-hospital cardiac arrest cohort including years 2012-2024.
SETTING: Participating hospitals from the American Heart Association Get With The Guidelines-Resuscitation registry.
PARTICIPANTS: Adult patients (≥18 years) who suffered in-hospital cardiac arrest.
EXPOSURE: Meeting a previously described termination of resuscitation rule.
MAIN OUTCOME: Survival to hospital discharge. Positive rates, false positive rates, false discovery rates, and resuscitation time potentially avoided were calculated. Hypothesis formulated prior to analysis.
RESULTS: Of 646,794 patients, 359,686 met inclusion criteria across 703 hospitals. Overall survival to discharge was 23.1%. For the primary Scandinavian termination Rule 1, the positive rate (patients meeting Rule criteria) was 1.7%; 32.9% of whom achieved return of spontaneous circulation and 5.1% survived to discharge. Median resuscitation time potentially avoided was 11 min per patient meeting Rule 1 criteria, equating to ∼18 min per 100 events. Across hospitals, positive rates ranged from 0% to 11.9. Other termination rules demonstrated either very low average positive rates (<3%) or unacceptably high survival rates among patients meeting the rule. Findings were similar in sensitivity analyses excluding the COVID-19 era.
CONCLUSIONS: In this large American cohort, previously derived termination rules for in-hospital cardiac arrest demonstrated either limited applicability or unacceptable error rates. Even the best-performing Scandinavian rule identified few patients for early termination and would have led to premature cessation in ∼5% of survivors. These findings underscore the need for further refinement of termination rules before clinical adoption in the United States.
参考来源
- Moskowitz A, Holmberg MJ, Kimbrell JM, et al. External validation of rules for termination of resuscitation in in-hospital cardiac arrest. Resuscitation. 2026. PMID: 41707975. doi:10.1016/j.resuscitation.2026.111019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。